Union Minister Ashwini Vaishnaw announced that India's Semicon 2.0 will focus on full product development, prioritizing ...

Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors ...

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ulcerative colitis will be the focus of a brief oral ...

Selecting the right software development agency is one of the most critical decisions a business can make. It’s a choice that ...

HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / / Medicus Pharma Ltd. ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

Despite the acquisition, Statsig will retain its operational independence, continuing to function out of its Seattle office. This approach allows OpenAI to benefit from Statsig's specialized knowledge ...

When design environments function seamlessly, engineers spend time engineering instead of wrestling with files or tools.

BNB surges past $900 to $920 following Franklin Templeton partnership. Strong institutional demand and market momentum hint ...

Traditional microbial expression systems can be advanced through improved plasmid replication, target gene transcription, ...

"We are thrilled to reach our target enrollment in the AFFIRM-1 trial evaluating BNC-210 as a transformative therapeutic for ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Spinal Cord Injury pipeline constitutes 25+ ...